115 results
6-K
EX-99.1
ALVO
Alvotech
22 May 24
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
6:30am
, at 8:00 am EDT (12:00 pm GMT). Registration for the conference call and access to the live webcast is found on https://investors.alvotech.com/events
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
9:00am
President, U.S. Market Access at Teva. “Biosimilars create opportunities for cost savings across the healthcare system, and SIMLANDI’s launch now … to ensure access to SIMLANDI, as well as the six other biosimilars we are committed to bringing to market by 2027.”
SIMLANDI is approved by the U.S
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
8:41am
into the highly regulated markets. We look forward to leveraging our strong commercial capabilities in these markets to ensure patients receive access to best … . “Dr. Reddy’s shares our commitment to provide better access to safe and effective biologics. Biosimilars play an increasingly important role in global
6-K
EX-99.1
ALVO
Alvotech
30 Apr 24
Current report (foreign)
8:00am
to more patients. Our intent is to offer a copay assistance program, which will provide eligible patients access,” said John Caufield, President … aim to increase healthcare access and ensure that affordable high-quality biologics are available to patients in need,” said Robert Wessman, Chairman
6-K
EX-99.1
ALVO
Alvotech
19 Apr 24
Current report (foreign)
8:05am
EXHIBIT 99.1
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab … approved high-concentration interchangeable biosimilar to Humira®
The agreement broadens patient access and further commitment to availability of vital
6-K
EX-99.1
gn3 xeq7ybk4z
16 Apr 24
Current report (foreign)
6:30pm
6-K
EX-99.1
akar2n
23 Feb 24
Current report (foreign)
8:39pm
6-K
EX-99.1
m57ym571vv
15 Feb 24
Current report (foreign)
4:00pm
6-K
EX-99.1
1z0dod s8xbe
10 Jan 24
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
7:00am
6-K
EX-99.1
xqrs43gbztyxa
29 Nov 23
Current report (foreign)
7:00am
6-K
EX-99.1
chdx5wio71
14 Nov 23
Current report (foreign)
4:30pm
6-K
EX-99.1
h5k va8v7rz3rrqfnj
13 Nov 23
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
6:15am
F-3
z1k hmbjzmq
20 Oct 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
xgymi5tow9ukgryv
3 Oct 23
Current report (foreign)
8:51am
6-K
EX-99.1
0gf w086fl38q11
25 Sep 23
Current report (foreign)
4:30pm
6-K/A
EX-99.1
4g9bi40kg8rt90xe3o7
7 Sep 23
Current report (foreign) (amended)
1:06pm
6-K
EX-99.1
j2pbn7
31 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.2
ehi44ri b2clevxt
31 Aug 23
Current report (foreign)
8:00am
424B3
g8r7d4o
24 Jul 23
Prospectus supplement
8:03am